Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Lunch and Poster Display session

247P - Financial and time burden associated with living with a metastatic breast cancer (MBC) diagnosis in Ireland: An all-Ireland patient-led survey (CTRIAL-IE 23-05)

Date

16 May 2024

Session

Lunch and Poster Display session

Presenters

Rachel Keogh

Citation

Annals of Oncology (2024) 9 (suppl_4): 1-47. 10.1016/esmoop/esmoop103200

Authors

R. Keogh1, S. Gaynor2, E. Mulvaney3, F.K. Duane4, C. Weadick5, H. Greally6, Y. O'Meara7, J.A. McBrien8, E. Mulroe3, I. Beristain3, M.J. O’leary9, I. Teiserskyte3, J. Marron3, S. McLoughlin2, V. Donachie3, S. O'Reilly10

Author affiliations

  • 1 Galway University Hospital, D09 FT51 - Galway/IE
  • 2 Cancer Trials Ireland, St Stephens Green/IE
  • 3 Cancer Trials Ireland, Dublin/IE
  • 4 St Luke's Radiation Oncology Network and Trinity St. James' Cancer Institute, Dublin/IE
  • 5 CUH - Cork University Hospital, Cork/IE
  • 6 Cancer Care West, Galway/IE
  • 7 University College Dublin, Dublin/IE
  • 8 Metastatic Breast Cancer Patient, Belfast/GB
  • 9 Marymount University Hospital & Hospice, Cork/IE
  • 10 Cancer Trials Ireland and Cork University Hospital, Dublin/IE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 247P

Background

Therapeutic advances have improved MBC survival rates but patient expressed needs such as time and financial toxicity have not been evaluated in Ireland to date.

Methods

An anonymous online survey in 9 domains was designed by a cohort of 30 MBC patients facilitated by a multidisciplinary group. Patients with MBC ≥ 18 years living on the Island of Ireland were eligible to participate. The survey consisted of a mixture of open and closed questions and results were summarized by means of counts and percentages for categorical variables and by means of mean, standard deviation, median and range for continuous variables.

Results

Between July-October 2023, 246 patients completed the survey. Median age was 52.5. Overall, 70% reported visiting the hospital 1-3 days every 28 days, most commonly for bloods, treatment, and imaging. The majority of visits (58%) lasted between 1-3 hours with 6% reporting a duration of more than 6 hours for their hospital visits. In the past 6 months, 25% of respondents visited the emergency Department (ED), of whom 27% spent more than 24 hours in the ED. 28% of respondents were admitted to hospital in that timeframe, of whom 43% spent less than 5 days in hospital and 37% for 5-10 days. Assessing the time spent traveling to the hospital; 36% reported 30-60 mins and 29% reported less than 30 mins, 11% reported over 120 mins. 48% drove themselves, 38% were driven by others, 7% took public transport, and 1.6% used volunteer services. 42% reported spending over 60 hours in the last 6 months managing their MBC. 75% of patients worry about the financial problems they will have in the future as a result of their illness or treatment. 20% are unable to meet their monthly expenses. Over 66% are frustrated that they cannot work or contribute as much as they usually do. 23% would strongly agree that they are financial stressed, followed by 22% who would somewhat agree. 50% would agree that their illness has been a financial burden on them and their family.

Conclusions

A MBC diagnosis has a substantial financial and time impact for patients. Care may be improved by improving provider awareness and by provision of financial and social service navigators.

Legal entity responsible for the study

Cancer Trials Ireland.

Funding

Irish Cancer Society.

Disclosure

R. Keogh: Financial Interests, Personal, Other, Travel, Accommodation, Expenses: MSD, Janssen. Y. O'Meara: Financial Interests, Personal, Speaker’s Bureau: GSK, Pfizer; Financial Interests, Personal, Full or part-time Employment: Mater Private Hospital; Financial Interests, Institutional, Funding: UCD for the Irish Cancer Societies Women's Health Initiative - Pfizer, GSK, AZ. V. Donachie: Financial Interests, Personal, Research Grant: CSL Vifor, AstraZeneca; Financial Interests, Personal, Advisory Role: CSL Vifor, AstraZeneca. S. O'Reilly: Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Other, Travel, Accommodation, Expenses: Nordic, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.